About us

It’s our mission to increase human life expectancy through intelligence driven biosystem simulations to truly personalize patient treatment.

Fueling the acceleration of research and development in drug discovery, we create the tools needed for unprecedented medical breakthroughs to take place much earlier in the drug discovery and development timeline. It’s our intention to create innovative products in the medical industry that will increase the efficiency and effectiveness of healthcare worldwide.


The first generation of new standard of the pharmaceutical industry is upon us.

It’s powered by


Machine Learning Intelligence System

Ideal intersection of desirable ML features

Our Team Meet the team behind the tech

Jo Varshney

DVM/PhD, Founder & CEO

Hal Eisen

VP of Eng

Victor Antontsev

 Biomedical Eng,   Lead Modeling &  Simulation  Scientist

Neha Maharao

 PhD   Pharmaceutical   Sciences,   Lead DMPK   Scientist

Luke Ceo

MSc. Organic Chemistry/MBA, Head of Business Development & Operations

Yogesh Bundey

MS CS / Data Science,  AI/Machine Learning Engineer

Bo Yuan

MS Computer Science, Senior Full Stack Software Engineer

Jason Walsh

MS Physics / CS, Senior Software Engineer

Priyanka Arora

PhD Pharmaceutical Sciences, DMPK Scientist

Tolu Junaid

MD/PhD, Medical information


Alexander Harmsen

CEO-Iris Automation, Technical AI advisor

“VeriSIM will have a tremendous impact on the pharma space by raising the bar for what can be done in pre-clinical research, and improving upon a conventional process to become a computable efficient process”

Jared Seehafer

CEO-Enzyme, FDA compliance advisor

“Data from animal studies is often a rate-limiting step in the development of new drugs and medical devices. The promise of generating this data programmatically, without either the time or the ethical considerations involved in testing with live animals, will revolutionize the development of new medicines, and I believe that VeriSIM is the company that will make this revolution a reality”

VeriSIM Life is providing pharmaceutical scientists a competitive advantage to accelerate R&D decisions to bring more personalized drugs in the market.


Save millions of dollars in R&D while drastically reducing the need for excessive and unreliable animal clinical trials

Our customers recognize an average cost reduction of 50%.

Save years of time identifying compounds for potential treatment options and cure for diseases

Our customers save years by narrowing the sample size of which compounds to test.

Recognize accuracy and efficiency, far beyond what’s seen in animal testing

Our customers see improvements in efficiency and an increase in the number of new successful formulas



BIOiSIM is offering unprecedented value for the drug development industry

by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illness or disease.

Toxic drugs excluded,
saves time, $$$, and lives

What are people (or scientists) saying about VeriSIM Life?

“The cost and time of developing new medications have been growing for decades. Modeling and simulation approaches have potential to reduce the time and cost and restore sustainability to drug development. VeriSIM Life ​is on the leading edge of this next phase of drug development using AI and machine learning to more efficiently and effectively predict pharmacology of potential new drug candidates through pharmacokinetic and pharmacodynamic modeling and simulation. VeriSIM Life has the potential to help design better drugs, predict disease outcome, and select patients who would benefit from therapies; making the dream of personalized medicine a reality.”

(Eric Stefanich, Director-PK/PD – Genentech)

“VeriSIM’s disruptive inventions are a perfect example of value creation and insight into drug development”
(Dr. Anindya Bagchi, PhD – Prof. SBP Medical Discovery institute)

Our Partners and Supporters

We are partnering with top Pharmas and Academic labs to help de-risk R&D decisions and bring personalized new drugs to the market at a significant higher and accurate pace”

If you are looking to give your pharmaceutical company a competitive edge, GET IN TOUCH.

Our Investors

News and Publications